End-of-day quote
Taipei Exchange
23:00:00 14/05/2024 BST
|
5-day change
|
1st Jan Change
|
20.3
TWD
|
-0.73%
|
|
-3.56%
|
+3.71%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,136
|
1,276
|
2,688
|
3,154
|
3,794
|
2,407
|
Enterprise Value (EV)
1 |
874.3
|
853.6
|
2,364
|
2,989
|
3,372
|
2,398
|
P/E ratio
|
-5.59
x
|
-5.13
x
|
-20.9
x
|
-17.4
x
|
-24
x
|
-9.23
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.57
x
|
6.25
x
|
12.1
x
|
14.5
x
|
14
x
|
10.2
x
|
EV / Revenue
|
5.06
x
|
4.18
x
|
10.7
x
|
13.8
x
|
12.5
x
|
10.1
x
|
EV / EBITDA
|
-5.72
x
|
-4.91
x
|
-19.9
x
|
-18
x
|
-24
x
|
-8.56
x
|
EV / FCF
|
-10.1
x
|
-6.62
x
|
-44
x
|
-42.1
x
|
-38.4
x
|
-15.1
x
|
FCF Yield
|
-9.93%
|
-15.1%
|
-2.27%
|
-2.38%
|
-2.6%
|
-6.6%
|
Price to Book
|
3.19
x
|
2.22
x
|
5.96
x
|
11.9
x
|
7.26
x
|
28.9
x
|
Nbr of stocks (in thousands)
|
78,658
|
108,795
|
108,795
|
108,795
|
122,978
|
122,978
|
Reference price
2 |
14.44
|
11.73
|
24.71
|
28.99
|
30.85
|
19.57
|
Announcement Date
|
19/03/19
|
19/03/20
|
18/03/21
|
22/03/22
|
24/02/23
|
26/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
172.8
|
204.2
|
221.6
|
217.1
|
270.2
|
236.9
|
EBITDA
1 |
-152.8
|
-174
|
-119
|
-166.4
|
-140.6
|
-280.1
|
EBIT
1 |
-170.6
|
-187.3
|
-128.8
|
-175.5
|
-149
|
-288.6
|
Operating Margin
|
-98.71%
|
-91.75%
|
-58.12%
|
-80.83%
|
-55.12%
|
-121.83%
|
Earnings before Tax (EBT)
1 |
-172.5
|
-187.5
|
-126.1
|
-176.1
|
-146.4
|
-284.4
|
Net income
1 |
-174.5
|
-190.6
|
-128.8
|
-181.3
|
-152.9
|
-289.4
|
Net margin
|
-100.96%
|
-93.36%
|
-58.1%
|
-83.52%
|
-56.59%
|
-122.15%
|
EPS
2 |
-2.584
|
-2.289
|
-1.183
|
-1.667
|
-1.285
|
-2.120
|
Free Cash Flow
1 |
-86.86
|
-128.9
|
-53.7
|
-71.02
|
-87.84
|
-158.4
|
FCF margin
|
-50.25%
|
-63.13%
|
-24.23%
|
-32.72%
|
-32.51%
|
-66.86%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/19
|
19/03/20
|
18/03/21
|
22/03/22
|
24/02/23
|
26/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
262
|
423
|
324
|
165
|
422
|
8.77
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-86.9
|
-129
|
-53.7
|
-71
|
-87.8
|
-158
|
ROE (net income / shareholders' equity)
|
-61.8%
|
-40.9%
|
-25.1%
|
-50.7%
|
-38.9%
|
-95.5%
|
ROA (Net income/ Total Assets)
|
-29.5%
|
-22.2%
|
-13.7%
|
-25.3%
|
-19.4%
|
-44.3%
|
Assets
1 |
592
|
858.4
|
942.5
|
715.4
|
786.4
|
653.9
|
Book Value Per Share
2 |
4.530
|
5.300
|
4.150
|
2.430
|
4.250
|
0.6800
|
Cash Flow per Share
2 |
3.390
|
4.190
|
3.230
|
1.780
|
3.620
|
0.7000
|
Capex
1 |
0.45
|
3.26
|
0.91
|
4.29
|
2.15
|
3.53
|
Capex / Sales
|
0.26%
|
1.6%
|
0.41%
|
1.97%
|
0.8%
|
1.49%
|
Announcement Date
|
19/03/19
|
19/03/20
|
18/03/21
|
22/03/22
|
24/02/23
|
26/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +3.71% | 92.26M | | +31.37% | 588B | | -2.81% | 364B | | +20.51% | 326B | | +5.53% | 285B | | +14.83% | 239B | | +9.93% | 210B | | -6.95% | 200B | | +10.96% | 167B | | +0.19% | 161B |
Other Pharmaceuticals
|